{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:53:39Z","timestamp":1791546819703,"version":"4.3.4"},"reference-count":156,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020046","name":"DKMS Foundation UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35CA210084"],"award-info":[{"award-number":["R35CA210084"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031826","name":"American Society of Gene and Cell Therapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["K08HL168155"],"award-info":[{"award-number":["K08HL168155"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1053\/j.seminhematol.2026.09.001","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:09:39Z","timestamp":1788995379000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Making space for cures: Conditioning for autologous hematopoietic stem cell gene therapies"],"prefix":"10.1053","author":[{"given":"Zachary D.","family":"Crees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7733-5509","authenticated-orcid":false,"given":"Stephen P.","family":"Persaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0001","doi-asserted-by":"crossref","DOI":"10.1172\/JCI190034","article-title":"Curing autoimmune diabetes in mice with islet and hematopoietic cell transplantation after CD117 antibody-based conditioning","volume":"136","author":"Bhagchandani","year":"2026","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.09.001_bib0002","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.001_bib0003","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41408-021-00553-w","article-title":"Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis","volume":"11","author":"Kurosawa","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.09.001_bib0004","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.001_bib0005","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2337\/db14-0295","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis","volume":"63","author":"D'Addio","year":"2014","journal-title":"Diabetes"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0006","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"New Engl J Med"},{"issue":"Supplement 2","key":"10.1053\/j.seminhematol.2026.09.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-192022","article-title":"Reduced intensity haploidentical bone marrow transplantation in adults with severe sickle cell disease: BMT CTN 1507","volume":"142","author":"Kassim","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.09.001_bib0008","first-page":"1612","article-title":"Death but one unintended consequence of gene-therapy trial","volume":"164","author":"Sibbald","year":"2001","journal-title":"CMAJ"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.001_bib0009","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.09.001_bib0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"New Engl J Med"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.09.001_bib0011","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent beta-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"New Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.09.001_bib0012","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1053\/j.seminhematol.2026.09.001_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231174304","article-title":"Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide","volume":"14","author":"Crees","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.09.001_bib0014","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2026.09.001_bib0015","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fimmu.2017.00496","article-title":"Graft-versus-leukemia effect following hematopoietic stem cell transplantation for Leukemia","volume":"8","author":"Dickinson","year":"2017","journal-title":"Front Immunol."},{"issue":"3","key":"10.1053\/j.seminhematol.2026.09.001_bib0016","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010228","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: prevention, detection, and treatment","volume":"20","author":"Rautenberg","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.09.001_bib0018","doi-asserted-by":"crossref","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.09.001_bib0019","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.09.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.11.006","article-title":"Early mixed donor chimerism is a strong negative prognostic indicator in allogeneic stem cell transplant for AML and MDS","volume":"31","author":"Radford","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1053\/j.seminhematol.2026.09.001_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.45","article-title":"Amelioration of murine sickle cell disease by nonablative conditioning and gamma-globin gene-corrected bone marrow cells","volume":"2","author":"Pestina","year":"2015","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1053\/j.seminhematol.2026.09.001_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01791","article-title":"Chimerism in the realm of hematopoietic stem cell transplantation for non-malignant disorders: a perspective","volume":"11","author":"Zimmerman","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.001_bib0023","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3324\/haematol.2019.227561","article-title":"Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy","volume":"105","author":"Magnani","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0024","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0165-1110(86)90020-5","article-title":"Toxicological review of busulfan (Myleran)","volume":"168","author":"Bishop","year":"1986","journal-title":"Mutat Res"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.09.001_bib0025","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/bmt.2016.322","article-title":"Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML\/MDS patients","volume":"52","author":"Andersson","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30738","article-title":"Busulfan and subsequent malignancy: an evidence-based risk assessment","volume":"71","author":"Long-Boyle","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.09.001_bib0027","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.seminoncol.2013.09.013","article-title":"Therapy-related myelodysplasia and acute myeloid leukemia","volume":"40","author":"Bhatia","year":"2013","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.09.001_bib0028","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3324\/haematol.2016.150250","article-title":"Late effects of blood and marrow transplantation","volume":"102","author":"Inamoto","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.09.001_bib0029","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"New Engl J Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.09.001_bib0030","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/bmt.2015.171","article-title":"Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases","volume":"50","author":"Slatter","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.09.001_bib0031","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2016-03-704015","article-title":"Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience","volume":"128","author":"Morillo-Gutierrez","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.09.001_bib0032","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41591-018-0301-6","article-title":"Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ss-thalassemia","volume":"25","author":"Marktel","year":"2019","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2026.09.001_bib0033","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211013985","article-title":"Treosulfan-based conditioning for inborn errors of immunity","volume":"12","author":"Slatter","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.001_bib0034","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.bbmt.2019.05.005","article-title":"Gonadal function after Busulfan compared with treosulfan in children and adolescents undergoing allogeneic hematopoietic stem cell transplant","volume":"25","author":"Faraci","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.001_bib0035","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene autotemcel gene therapy for non-beta(0)\/beta(0) genotype beta-thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"New Engl J Med"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.09.001_bib0036","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene autotemcel for transfusion-dependent beta-thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"New Engl J Med"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.09.001_bib0037","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa2501277","article-title":"CRISPR-Cas12a gene editing of HBG1 and HBG2 promoters to treat beta-thalassemia","volume":"394","author":"Frangoul","year":"2026","journal-title":"New Engl J Med"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.09.001_bib0038","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJMoa2415550","article-title":"CRISPR-Cas12a gene editing of HBG1 and HBG2 promoters to treat sickle cell disease","volume":"394","author":"Hanna","year":"2026","journal-title":"New Engl J Med"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.09.001_bib0039","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2504835","article-title":"Base editing of HBG1 and HBG2 promoters for sickle cell disease","volume":"394","author":"Gupta","year":"2026","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41591-021-01554-9","article-title":"Lentiviral globin gene therapy with reduced-intensity conditioning in adults with beta-thalassemia: a phase 1 trial","volume":"28","author":"Boulad","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.09.001_bib0041","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/s41591-025-03662-2","article-title":"Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1\/2 trial","volume":"31","author":"Grimley","year":"2025","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2026.09.001_bib0042","article-title":"Etuvetidigene autotemcel for the treatment of Wiskott-Aldrich syndrome","author":"Ferrua","year":"2025","journal-title":"medRxiv"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.001_bib0043","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","article-title":"Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study","volume":"6","author":"Ferrua","year":"2019","journal-title":"Lancet Haematol"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.09.001_bib0044","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1056\/NEJMoa2407376","article-title":"Lentiviral gene therapy for severe leukocyte adhesion deficiency type 1","volume":"392","author":"Booth","year":"2025","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.2024026288","article-title":"How I treat Wiskott-Aldrich syndrome","volume":"146","author":"Vallee","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0046","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/blood-2007-04-082552","article-title":"Reversion mutations in patients with leukocyte adhesion deficiency type-1 (LAD-1)","volume":"111","author":"Uzel","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.09.001_bib0047","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41591-023-02789-4","article-title":"Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency","volume":"30","author":"Migliavacca","year":"2024","journal-title":"Nat Med"},{"issue":"21","key":"10.1053\/j.seminhematol.2026.09.001_bib0048","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"New Engl J Med"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.09.001_bib0049","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"New Engl J Med"},{"issue":"25","key":"10.1053\/j.seminhematol.2026.09.001_bib0050","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa2206575","article-title":"Lentiviral gene therapy for Artemis-deficient SCID","volume":"387","author":"Cowan","year":"2022","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.09.001_bib0051","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","article-title":"Lentiviral gene therapy for X-linked chronic granulomatous disease","volume":"26","author":"Kohn","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0052","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/mt.2010.232","article-title":"Gene therapy of chronic granulomatous disease: the engraftment dilemma","volume":"19","author":"Grez","year":"2011","journal-title":"Mol Ther"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.001_bib0053","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/bmt.2011.140","article-title":"Reduced-intensity conditioning hematopoietic SCT for pediatric patients with LAD-1: clinical efficacy and importance of chimerism","volume":"47","author":"Hamidieh","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.09.001_bib0054","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1542\/peds.2008-1191","article-title":"Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency","volume":"123","author":"Qasim","year":"2009","journal-title":"Pediatrics"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.09.001_bib0055","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1182\/blood.2022019117","article-title":"Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome","volume":"142","author":"Labrosse","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0056","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41591-021-01641-x","article-title":"Long-term safety and efficacy of lentiviral hematopoietic stem\/progenitor cell gene therapy for Wiskott-Aldrich syndrome","volume":"28","author":"Magnani","year":"2022","journal-title":"Nat Med"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.09.001_bib0057","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"New Engl J Med"},{"issue":"14","key":"10.1053\/j.seminhematol.2026.09.001_bib0058","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMoa2400442","article-title":"Lentiviral gene therapy for cerebral adrenoleukodystrophy","volume":"391","author":"Eichler","year":"2024","journal-title":"New Engl J Med"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.09.001_bib0059","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa2405727","article-title":"Long-term effects of atidarsagene autotemcel for metachromatic leukodystrophy","volume":"392","author":"Fumagalli","year":"2025","journal-title":"New Engl J Med"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.09.001_bib0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-141762","article-title":"Ex-vivo autologous stem cell gene therapy clinical trial for mucopolysaccharidosis type IIIA: trial in progress - NCT04201405","volume":"136","author":"Kinsella","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.09.001_bib0061","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1016\/j.jtct.2023.12.309","article-title":"Design of a multi-center randomized active controlled phase 3 clinical trial (HURCULES) evaluating the safety and efficacy of OTL-203 in patients with MPS-IH versus standard of care with allogeneic hematopoietic stem cell transplantation","volume":"30","author":"Gupta","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1053\/j.seminhematol.2026.09.001_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101125","article-title":"Clinical holds for cell and gene therapy trials: risks, impact, and lessons learned","volume":"31","author":"Wills","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"14","key":"10.1053\/j.seminhematol.2026.09.001_bib0063","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","article-title":"Hematologic cancer after gene therapy for cerebral adrenoleukodystrophy","volume":"391","author":"Duncan","year":"2024","journal-title":"New Engl J Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.09.001_bib0064","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1172\/JCI28873","article-title":"Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice","volume":"116","author":"Biffi","year":"2006","journal-title":"J Clin Invest"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.09.001_bib0065","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1182\/bloodadvances.2023010561","article-title":"Clearing and replacing tissue-resident myeloid cells with an anti-CD45 antibody-drug conjugate","volume":"7","author":"Gustafsson","year":"2023","journal-title":"Blood Adv"},{"issue":"37","key":"10.1053\/j.seminhematol.2026.09.001_bib0066","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1073\/pnas.1205858109","article-title":"Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation","volume":"109","author":"Capotondo","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"issue":"11","key":"10.1053\/j.seminhematol.2026.09.001_bib0067","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1073\/pnas.88.11.4771","article-title":"Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier","volume":"88","author":"Friden","year":"1991","journal-title":"Proc Natl Acad Sci USA."},{"issue":"796","key":"10.1053\/j.seminhematol.2026.09.001_bib0068","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ads6111","article-title":"Brain-wide microglia replacement using a nonconditioning strategy ameliorates pathology in mouse models of neurological disorders","volume":"17","author":"Chen","year":"2025","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.seminhematol.2026.09.001_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101225","article-title":"Longitudinal clinical manifestations of Fanconi anemia: a systematized review","volume":"68","author":"Hoover","year":"2024","journal-title":"Blood Rev"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.001_bib0070","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.09.001_bib0071","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/bloodadvances.2019001289","article-title":"Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia","volume":"4","author":"Abadir","year":"2020","journal-title":"Blood Adv"},{"issue":"25","key":"10.1053\/j.seminhematol.2026.09.001_bib0072","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1182\/blood.2024024636","article-title":"cMPL-based purification and depletion of human hematopoietic stem cells: implications for pretransplant conditioning","volume":"145","author":"Araki","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.09.001_bib0073","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood-2025-1065","article-title":"In Vivo hematopoietic stem cell (HSC) engineering and selection with CD90-targeted multiplexed virus-like particles (MVPs) for HSC gene therapy and cancer immunotherapy","volume":"146","author":"Radtke","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0074","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41467-018-08201-x","article-title":"Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation","volume":"10","author":"Czechowicz","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.09.001_bib0075","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.09.001_bib0076","doi-asserted-by":"crossref","DOI":"10.3390\/toxins15030181","article-title":"Streptavidin-saporin: converting biotinylated materials into targeted toxins","volume":"15","author":"Ancheta","year":"2023","journal-title":"Toxins (Basel)"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0077","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1038\/s41467-025-60464-3","article-title":"A non-genotoxic stem cell therapy boosts lymphopoiesis and averts age-related blood diseases in mice","volume":"16","author":"Konturek-Ciesla","year":"2025","journal-title":"Nat Commun"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.09.001_bib0078","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/bloodadvances.2019000516","article-title":"Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice","volume":"3","author":"Gao","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0079","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41467-018-08202-w","article-title":"Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody-drug-conjugate conditioning in MHC-mismatched allotransplantation","volume":"10","author":"Li","year":"2019","journal-title":"Nat Commun"},{"issue":"24","key":"10.1053\/j.seminhematol.2026.09.001_bib0080","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145501","article-title":"Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation","volume":"131","author":"Persaud","year":"2021","journal-title":"J Clin Invest"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.09.001_bib0081","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-157726","article-title":"Fully myeloablative antibody-drug conjugates condition for hematopoietic stem cell transplantation and provide durable antileukemia benefit","volume":"140","author":"Persaud","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.09.001_bib0082","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1182\/blood.2021012366","article-title":"A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice","volume":"139","author":"Saha","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2026.09.001_bib0083","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1182\/blood.2023023549","article-title":"Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate-conditioned Fanconi anemia mice","volume":"143","author":"Saha","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.09.001_bib0084","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2020.264432","article-title":"Endogenous and combination retinoids are active in myelomonocytic leukemias","volume":"106","author":"Di Martino","year":"2021","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.09.001_bib0085","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1182\/blood-2025-5956","article-title":"Motixafortide (CXCR4 inhibition) alone and in combination with natalizumab (VLA-4 inhibition) to mobilize hematopoietic stem cells for gene therapy in sickle cell disease: a first-in-human, safety and feasibility study","volume":"146","author":"Crees","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.09.001_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.bict.2025.100012","article-title":"Streptavidin-drug conjugates streamline optimization of antibody-based hematopoietic stem cell transplant conditioning","volume":"1","author":"Yelamali","year":"2025","journal-title":"Blood Immunol Cell Ther"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.09.001_bib0087","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.ymthe.2024.03.032","article-title":"Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant","volume":"32","author":"Yeung","year":"2024","journal-title":"Mol Ther"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.09.001_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2024.10.014","article-title":"BCL11A +58\/+55 enhancer-editing facilitates HSPC engraftment and HbF induction in rhesus macaques conditioned with a CD45 antibody-drug conjugate","volume":"32","author":"Demirci","year":"2025","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0089","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1038\/s41467-023-41153-5","article-title":"Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model","volume":"14","author":"Uchida","year":"2023","journal-title":"Nat Commun"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.09.001_bib0090","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2025-5871","article-title":"Refined design of a CD117 antibody-drug conjugate safely and effectively conditions non-human primates for autologous transplant-based gene therapy","volume":"146","author":"Gorfinkel","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.09.001_bib0091","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2021-145524","article-title":"CD117 Antibody drug conjugate-based conditioning allows for efficient engraftment of gene-modified CD34+ cells in a Rhesus Gene Therapy model","volume":"138","author":"Uchida","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.09.001_bib0092","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/bloodadvances.2025017838","article-title":"Engraftment of gene-edited hematopoietic stem cells after antibody-drug conjugate conditioning in nonhuman primates","volume":"10","author":"Murray","year":"2026","journal-title":"Blood Adv"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.09.001_bib0093","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1016\/j.ymthe.2026.04.010","article-title":"Restoration of the immune system with base editing and non-genotoxic conditioning in a Rag2 point-mutant mouse model","volume":"34","author":"Dib","year":"2026","journal-title":"Mol Ther"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.09.001_bib0094","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.bbmt.2018.12.101","article-title":"A CD117-amanitin antibody drug conjugate (ADC) effectively depletes human and non-human primate hematopoietic stem and progenitor cells (HSPCs)<em>:<\/em>targeted non-genotoxic conditioning for bone marrow transplant","volume":"25","author":"Pearse","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.09.001_bib0095","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.09.001_bib0096","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bbmt.2019.11.007","article-title":"Radioimmunotherapy in combination with reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with advanced multiple myeloma","volume":"26","author":"Fasslrinner","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.001_bib0097","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/bjh.13773","article-title":"High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma","volume":"171","author":"Cassaday","year":"2015","journal-title":"Brit J Haematol"},{"issue":"23","key":"10.1053\/j.seminhematol.2026.09.001_bib0098","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1182\/blood-2009-02-205476","article-title":"131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-hodgkin lymphoma","volume":"113","author":"Gopal","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.001_bib0099","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood.V83.5.1390.1390","article-title":"Retention of B-cell-specific monoclonal antibodies by human lymphoma cells","volume":"83","author":"Press","year":"1994","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.001_bib0100","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.bbmt.2014.05.014","article-title":"Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome","volume":"20","author":"Mawad","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"10.1053\/j.seminhematol.2026.09.001_bib0101","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1182\/blood-2009-03-213298","article-title":"Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"114","author":"Pagel","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.001_bib0102","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood-2005-06-2317","article-title":"131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission","volume":"107","author":"Pagel","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.09.001_bib0103","article-title":"Randomized phase III SIERRA trial of (131)I-Apamistamab before allogeneic hematopoietic cell transplantation versus conventional care for relapsed\/refractory AML","author":"Gyurkocza","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.09.001_bib0104","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood.2026033789","article-title":"[211At]Astatine-based conditioning with a humanized CD45 antibody for autologous hematopoietic stem cell gene therapy","volume":"148","author":"Radtke","year":"2026","journal-title":"Blood"},{"issue":"5854","key":"10.1053\/j.seminhematol.2026.09.001_bib0105","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1126\/science.1149726","article-title":"Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches","volume":"318","author":"Czechowicz","year":"2007","journal-title":"Science"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.09.001_bib0106","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood-2015-12-689083","article-title":"KIT blockade is sufficient for donor hematopoietic stem cell engraftment in Fanconi anemia mice","volume":"129","author":"Chandrakasan","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.09.001_bib0107","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood-2002-08-2379","article-title":"Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation","volume":"101","author":"Wulf","year":"2003","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminhematol.2026.09.001_bib0108","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1182\/blood-2010-07-295949","article-title":"Antibody targeting KIT as pretransplantation conditioning in immunocompetent mice","volume":"116","author":"Xue","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0109","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1186\/s13287-024-03981-0","article-title":"Targeted hematopoietic stem cell depletion through SCF-blockade","volume":"15","author":"Chan","year":"2024","journal-title":"Stem Cell Res Ther"},{"issue":"351","key":"10.1053\/j.seminhematol.2026.09.001_bib0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aae0501","article-title":"Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy","volume":"8","author":"Chhabra","year":"2016","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.09.001_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2019.05.018","article-title":"Antibody conditioning enables MHC-mismatched hematopoietic stem cell transplants and organ graft tolerance","volume":"25","author":"George","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.09.001_bib0112","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1182\/bloodadvances.2023012457","article-title":"Conditioning with anti-CD47 and anti-CD117 plus JAK inhibition enables toxic payload-free allogeneic transplantation","volume":"8","author":"Persaud","year":"2024","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.09.001_bib0113","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2024-200305","article-title":"Anti-CD117 plus anti-sirp\u03b1 or fc-silenced anti-CD47 enables hematopoietic stem cell depletion and syngeneic engraftment without development of severe anemia","volume":"144","author":"Persaud","year":"2024","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.09.001_bib0114","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2018-06-858159","article-title":"Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice","volume":"133","author":"Pang","year":"2019","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.09.001_bib0115","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood-2018-06-853879","article-title":"Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice","volume":"133","author":"Kwon","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.09.001_bib0116","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2021-153074","article-title":"JSP191 As a single-agent conditioning regimen results in successful engraftment, donor myeloid chimerism, and production of donor derived naive lymphocytes in patients with severe combined immunodeficiency (SCID)","volume":"138","author":"Agarwal","year":"2021","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.09.001_bib0117","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/blood.2025031858","article-title":"Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS","volume":"147","author":"Muffly","year":"2026","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.001_bib0118","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41591-025-03817-1","article-title":"Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial","volume":"31","author":"Agarwal","year":"2025","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.09.001_bib0119","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2024-200214","article-title":"Adding CD117 antibody to alemtuzumab, low dose total body irradiation (TBI), and sirolimus for matched related donor (MRD) hematopoietic cell transplant (HCT) in Sickle Cell disease (SCD): initial results","volume":"144","author":"Hsieh","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.001_bib0120","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.ymthe.2018.03.003","article-title":"Myeloid conditioning with c-kit-targeted CAR-T cells enables donor stem cell engraftment","volume":"26","author":"Arai","year":"2018","journal-title":"Mol Ther"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.001_bib0121","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3324\/haematol.2008.001677","article-title":"Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy","volume":"94","author":"Griffioen","year":"2009","journal-title":"Haematologica"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.09.001_bib0122","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"New Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.09.001_bib0123","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.bbmt.2007.04.005","article-title":"Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation","volume":"13","author":"Tey","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0124","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1525-0016(03)00142-4","article-title":"Transduction and selection of human T cells with novel CD34\/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease","volume":"8","author":"Rettig","year":"2003","journal-title":"Mol Ther"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.001_bib0125","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Ciceri","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2026.09.001_bib0126","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.omto.2023.07.003","article-title":"Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells","volume":"30","author":"Magnani","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"10.1053\/j.seminhematol.2026.09.001_bib0127","article-title":"Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy","volume":"29","author":"Inthanachai","year":"2026","journal-title":"Immunooncol Technol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.09.001_bib0128","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell."},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.001_bib0129","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/s41591-026-04362-1","article-title":"CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1\/2 trial","volume":"32","author":"DiPersio","year":"2026","journal-title":"Nat Med"},{"issue":"714","key":"10.1053\/j.seminhematol.2026.09.001_bib0130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi1145","article-title":"Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy","volume":"15","author":"Wellhausen","year":"2023","journal-title":"Sci Transl Med"},{"issue":"7978","key":"10.1053\/j.seminhematol.2026.09.001_bib0131","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.09.001_bib0132","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231235","article-title":"Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy","volume":"220","author":"Marone","year":"2023","journal-title":"J Exp Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.09.001_bib0133","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2024.09.003","article-title":"Epitope prime editing shields hematopoietic cells from CD123 immunotherapy for acute myeloid leukemia","volume":"31","author":"Ji","year":"2024","journal-title":"Cell Stem Cell"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.001_bib0134","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \"off-the-shelf\" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.09.001_bib0135","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood.2025028387","article-title":"Phase 1\/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed\/refractory T-cell malignancies","volume":"146","author":"Ghobadi","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.09.001_bib0136","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2026.03.047","article-title":"Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse","volume":"189","author":"Gattinoni","year":"2026","journal-title":"Cell"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.09.001_bib0137","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/bloodadvances.2024015157","article-title":"Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies","volume":"9","author":"Shahid","year":"2025","journal-title":"Blood Adv"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.09.001_bib0138","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.09.001_bib0139","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","volume":"43","author":"Li","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1053\/j.seminhematol.2026.09.001_bib0140","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/s41551-025-01527-0","article-title":"CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy","volume":"10","author":"Ramirez-Fernandez","year":"2025","journal-title":"Nat Biomed Eng"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.09.001_bib0141","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2025016927","article-title":"HLA-E single-chain trimer shields gene-edited allogeneic CAR T cells from NK cell attack","volume":"10","author":"Apodaca","year":"2026","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.001_bib0142","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008417","article-title":"Stealth transgenes enable CAR-T cells to evade host immune responses","volume":"12","author":"Grauwet","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.001_bib0143","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2025.07.009","article-title":"Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease","volume":"32","author":"Hu","year":"2025","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0144","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","article-title":"Engineered off-the-shelf therapeutic T cells resist host immune rejection","volume":"39","author":"Mo","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"6656","key":"10.1053\/j.seminhematol.2026.09.001_bib0145","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2026.09.001_bib0146","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105777","article-title":"Antibody conjugated lipid nanoparticles as a targeted drug delivery system for hydrophobic pharmaceuticals","volume":"161","author":"Notabi","year":"2021","journal-title":"Eur J Pharm Sci"},{"issue":"6576","key":"10.1053\/j.seminhematol.2026.09.001_bib0147","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.09.001_bib0148","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1182\/bloodadvances.2024012757","article-title":"A simplified G-CSF-free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model","volume":"8","author":"Li","year":"2024","journal-title":"Blood Adv"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.09.001_bib0149","first-page":"2085","article-title":"In vivo HSC prime editing rescues sickle cell disease in a mouse model","volume":"141","author":"Li","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.09.001_bib0150","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.ymthe.2024.10.018","article-title":"Introducing a hemoglobin G-makassar variant in HSCs by in vivo base editing treats sickle cell disease in mice","volume":"32","author":"Li","year":"2024","journal-title":"Mol Ther"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.001_bib0151","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101438","article-title":"Highly efficient in vivo hematopoietic stem cell transduction using an optimized self-complementary adeno-associated virus","volume":"33","author":"Charlesworth","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"24","key":"10.1053\/j.seminhematol.2026.09.001_bib0152","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1182\/bloodadvances.2025016775","article-title":"In situ gene editing of hematopoietic stem cells via AAV-delivered CRISPR guide RNAs","volume":"9","author":"Karimzadeh","year":"2025","journal-title":"Blood Adv"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.09.001_bib0153","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.ymthe.2025.07.006","article-title":"Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector","volume":"33","author":"Coradin","year":"2025","journal-title":"Mol Ther"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.001_bib0154","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.2024024523","article-title":"In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.001_bib0155","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41565-024-01680-8","article-title":"Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells","volume":"19","author":"Lian","year":"2024","journal-title":"Nat Nanotechnol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.09.001_bib0156","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1182\/blood-2024-194638","article-title":"Lentiviral-mediated gene therapy for patients with Fanconi anemia [Group a]: updated results from global RP-L102 clinical trials","volume":"144","author":"Czechowicz","year":"2024","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:23:45Z","timestamp":1791545025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":156,"alternative-id":["S0037196326000867"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.09.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Making space for cures: Conditioning for autologous hematopoietic stem cell gene therapies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}